$1.40
5.41% today
Nasdaq, Apr 02, 10:18 pm CET
ISIN
US74039M1018
Symbol
POAI

Predictive Oncology Inc Stock price

$1.48
+0.22 17.46% 1M
+0.70 89.57% 6M
+0.66 80.49% YTD
-0.79 34.80% 1Y
-17.12 92.04% 3Y
-26.52 94.71% 5Y
-15,248.52 99.99% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.04 2.63%
ISIN
US74039M1018
Symbol
POAI
Sector

Key metrics

Market capitalization $10.67m
Enterprise Value $9.99m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.24
P/S ratio (TTM) P/S ratio 7.73
P/B ratio (TTM) P/B ratio 5.02
Revenue growth (TTM) Revenue growth -23.75%
Revenue (TTM) Revenue $1.38m
EBIT (operating result TTM) EBIT $-13.25m
Free Cash Flow (TTM) Free Cash Flow $-12.00m
Cash position $3.08m
EPS (TTM) EPS $-3.06
P/S forward 7.86
EV/Sales forward 7.37
Short interest 5.58%
Show more

Is Predictive Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Predictive Oncology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Predictive Oncology Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Predictive Oncology Inc:

Hold
100%

Financial data from Predictive Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.38 1.38
24% 24%
100%
- Direct Costs 1.31 1.31
10% 10%
95%
0.07 0.07
80% 80%
5%
- Selling and Administrative Expenses 13 13
9% 9%
927%
- Research and Development Expense - -
-
-
-13 -13
9% 9%
-922%
- Depreciation and Amortization 0.52 0.52
43% 43%
38%
EBIT (Operating Income) EBIT -13 -13
11% 11%
-960%
Net Profit -14 -14
24% 24%
-1,012%

In millions USD.

Don't miss a Thing! We will send you all news about Predictive Oncology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Predictive Oncology Inc Stock News

Neutral
GlobeNewsWire
one day ago
PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended Dec...
Neutral
GlobeNewsWire
8 days ago
Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan
Neutral
GlobeNewsWire
13 days ago
Deal positions STREAMWAY ® Systems with an established market leader to drive accelerating growth
More Predictive Oncology Inc News

Company Profile

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Domestic, International, and Helomics. The Domestic and International segments focuses on STREAMWAY System product sales. The Helomics segment comprises of clinical testing and contract research. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.

Head office United States
CEO Raymond Vennare
Founded 2002
Website predictive-oncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today